Compile Data Set for Download or QSAR
Found 1601 with Last Name = 'tavares' and Initial = 'fx'
TargetGlycogen synthase kinase-3 beta(Homo sapiens (Human))
GlaxoSmithKline

LigandPNGBDBM8143(N-[3-bromo-5-(trifluoromethyl)phenyl]-4-{pyrazolo[...)
Affinity DataKi:  0.300nM IC50: <10nMAssay Description:The biochemical activity of compounds was determined by incubation with specific enzyme and substrate in the presence 2.5 uM ATP/ [gamma-32P] ATP. Af...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetGlycogen synthase kinase-3 beta(Homo sapiens (Human))
GlaxoSmithKline

LigandPNGBDBM8146(N-(3,5-dimethylphenyl)-4-{pyrazolo[1,5-a]pyridazin...)
Affinity DataKi:  1nM IC50: <10nMAssay Description:The biochemical activity of compounds was determined by incubation with specific enzyme and substrate in the presence 2.5 uM ATP/ [gamma-32P] ATP. Af...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetGlycogen synthase kinase-3 beta(Homo sapiens (Human))
GlaxoSmithKline

LigandPNGBDBM8145(N-(3,5-dichlorophenyl)-4-{pyrazolo[1,5-a]pyridazin...)
Affinity DataKi:  1nM IC50: <10nMAssay Description:The biochemical activity of compounds was determined by incubation with specific enzyme and substrate in the presence 2.5 uM ATP/ [gamma-32P] ATP. Af...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetGlycogen synthase kinase-3 beta(Homo sapiens (Human))
GlaxoSmithKline

LigandPNGBDBM8136(N-(2,3-dihydro-1,4-benzodioxin-6-yl)-4-{pyrazolo[1...)
Affinity DataKi:  1nM IC50: <10nMAssay Description:The biochemical activity of compounds was determined by incubation with specific enzyme and substrate in the presence 2.5 uM ATP/ [gamma-32P] ATP. Af...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetGlycogen synthase kinase-3 beta(Homo sapiens (Human))
GlaxoSmithKline

LigandPNGBDBM8138(N-(3,4-dihydro-2H-1,5-benzodioxepin-7-yl)-4-{pyraz...)
Affinity DataKi:  1nM IC50: <10nMAssay Description:The biochemical activity of compounds was determined by incubation with specific enzyme and substrate in the presence 2.5 uM ATP/ [gamma-32P] ATP. Af...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetGlycogen synthase kinase-3 beta(Homo sapiens (Human))
GlaxoSmithKline

LigandPNGBDBM8144(N-(3,5-difluorophenyl)-4-{pyrazolo[1,5-a]pyridazin...)
Affinity DataKi:  2nM IC50: <10nMAssay Description:The biochemical activity of compounds was determined by incubation with specific enzyme and substrate in the presence 2.5 uM ATP/ [gamma-32P] ATP. Af...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetGlycogen synthase kinase-3 beta(Homo sapiens (Human))
GlaxoSmithKline

LigandPNGBDBM8142(N-[3-methoxy-5-(trifluoromethyl)phenyl]-4-{pyrazol...)
Affinity DataKi:  2nM IC50: <10nMAssay Description:The biochemical activity of compounds was determined by incubation with specific enzyme and substrate in the presence 2.5 uM ATP/ [gamma-32P] ATP. Af...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetGlycogen synthase kinase-3 beta(Homo sapiens (Human))
GlaxoSmithKline

LigandPNGBDBM8171(N-(2,3-dihydro-1,4-benzodioxin-6-yl)-4-{2-phenylpy...)
Affinity DataKi:  2nM IC50: <10nMAssay Description:The biochemical activity of compounds was determined by incubation with specific enzyme and substrate in the presence 2.5 uM ATP/ [gamma-32P] ATP. Af...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetGlycogen synthase kinase-3 beta(Homo sapiens (Human))
GlaxoSmithKline

LigandPNGBDBM8135(N-(2H-1,3-benzodioxol-5-yl)-4-{pyrazolo[1,5-a]pyri...)
Affinity DataKi:  2nM IC50: <10nMAssay Description:The biochemical activity of compounds was determined by incubation with specific enzyme and substrate in the presence 2.5 uM ATP/ [gamma-32P] ATP. Af...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetGlycogen synthase kinase-3 beta(Homo sapiens (Human))
GlaxoSmithKline

LigandPNGBDBM8130(N-(4-nitrophenyl)-4-{pyrazolo[1,5-a]pyridazin-3-yl...)
Affinity DataKi:  2nM IC50: <10nMAssay Description:The biochemical activity of compounds was determined by incubation with specific enzyme and substrate in the presence 2.5 uM ATP/ [gamma-32P] ATP. Af...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetGlycogen synthase kinase-3 beta(Homo sapiens (Human))
GlaxoSmithKline

LigandPNGBDBM8129(4-[(4-{pyrazolo[1,5-a]pyridazin-3-yl}pyrimidin-2-y...)
Affinity DataKi:  2nM IC50: <10nMAssay Description:The biochemical activity of compounds was determined by incubation with specific enzyme and substrate in the presence 2.5 uM ATP/ [gamma-32P] ATP. Af...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetGlycogen synthase kinase-3 beta(Homo sapiens (Human))
GlaxoSmithKline

LigandPNGBDBM8140(N-[4-chloro-3-(trifluoromethyl)phenyl]-4-{pyrazolo...)
Affinity DataKi:  2nM IC50: <10nMAssay Description:The biochemical activity of compounds was determined by incubation with specific enzyme and substrate in the presence 2.5 uM ATP/ [gamma-32P] ATP. Af...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCathepsin K(Homo sapiens (Human))
GlaxoSmithKline

Curated by ChEMBL
LigandPNGBDBM50163831((2S)-1-cyclohexylpropan-2-yl 1-cyanoazetidine-2-ca...)
Affinity DataIC50:  0.0480nMAssay Description:Inhibitory concentration against human cathepsin K using 10 uM Cbz-Phe-Arg-AMCMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCathepsin K(Homo sapiens (Human))
GlaxoSmithKline

Curated by ChEMBL
LigandPNGBDBM19783((2S)-3,3-dimethyl-1-{3-[4-(trifluoromethyl)phenyl]...)
Affinity DataIC50:  0.0720nMpH: 5.5 T: 2°CAssay Description:Assays were carried out in the presence of variable concentrations of test compound. Reactions were initiated by addition of enzyme to buffered solut...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCathepsin K(Homo sapiens (Human))
GlaxoSmithKline

Curated by ChEMBL
LigandPNGBDBM50148310(((S)-1-Formyl-pentyl)-carbamic acid (S)-1-benzyl-p...)
Affinity DataIC50:  0.130nMAssay Description:Inhibitory concentration against human cathepsin K using 10 uM Cbz-Phe-Arg-AMCMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Homo sapiens (Human))
GI Therapeutics, Inc.

US Patent
LigandPNGBDBM253965(US9464092, EEE | US9527857, EEE)
Affinity DataIC50:  0.200nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Homo sapiens (Human))
GI Therapeutics, Inc.

US Patent
LigandPNGBDBM253965(US9464092, EEE | US9527857, EEE)
Affinity DataIC50:  0.200nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCathepsin K(Homo sapiens (Human))
GlaxoSmithKline

Curated by ChEMBL
LigandPNGBDBM50138858(CHEMBL154579 | [(S)-1-(4-Phenyl-1H-pyrazol-3-ylami...)
Affinity DataIC50:  0.210nMAssay Description:Concentration required to inhibit 50% of cysteine protease cathepsin K of humanMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCathepsin S(Homo sapiens (Human))
GSK

LigandPNGBDBM19783((2S)-3,3-dimethyl-1-{3-[4-(trifluoromethyl)phenyl]...)
Affinity DataIC50:  0.210nMAssay Description:Assays were carried out in the presence of variable concentrations of test compound. Reactions were initiated by addition of enzyme to buffered solut...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCathepsin K(Homo sapiens (Human))
GlaxoSmithKline

Curated by ChEMBL
LigandPNGBDBM50138853(CHEMBL157072 | [(S)-1-(4-Bromo-1H-pyrazol-3-ylamin...)
Affinity DataIC50:  0.240nMAssay Description:Concentration required to inhibit 50% of cysteine protease cathepsin K of humanMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCathepsin K(Homo sapiens (Human))
GlaxoSmithKline

Curated by ChEMBL
LigandPNGBDBM50138876(CHEMBL345569 | [(S)-1-(4-Fluoro-1H-indazol-3-ylami...)
Affinity DataIC50:  0.260nMAssay Description:Concentration required to inhibit 50% of cysteine protease cathepsin K of humanMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetMelanin-concentrating hormone receptor 1(Homo sapiens (Human))
GlaxoSmithKline

Curated by ChEMBL
LigandPNGBDBM50199266(6-(4-chlorophenyl)-3-[6-(1-piperidinylmethyl)-2-na...)
Affinity DataIC50:  0.390nMAssay Description:Antagonist activity against human MCH1 receptor stably-expressed in CHO cells by Gal4/Elk1-Luc reporter assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Homo sapiens (Human))
GI Therapeutics, Inc.

US Patent
LigandPNGBDBM253910(US9464092, B | US9527857, B)
Affinity DataIC50:  0.400nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Homo sapiens (Human))
GI Therapeutics, Inc.

US Patent
LigandPNGBDBM253910(US9464092, B | US9527857, B)
Affinity DataIC50:  0.400nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Homo sapiens (Human))
GI Therapeutics, Inc.

US Patent
LigandPNGBDBM253910(US9464092, B | US9527857, B)
Affinity DataIC50:  0.400nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCathepsin K(Homo sapiens (Human))
GlaxoSmithKline

Curated by ChEMBL
LigandPNGBDBM50138866(CHEMBL156764 | [(S)-1-(1-Methyl-1H-pyrazol-3-ylami...)
Affinity DataIC50:  0.410nMAssay Description:Concentration required to inhibit 50% of cysteine protease cathepsin K of humanMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCathepsin K(Homo sapiens (Human))
GlaxoSmithKline

Curated by ChEMBL
LigandPNGBDBM50138869(CHEMBL154959 | [(S)-1-(4-Methyl-1H-pyrazol-3-ylami...)
Affinity DataIC50:  0.470nMAssay Description:Concentration required to inhibit 50% of cysteine protease cathepsin K of humanMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Homo sapiens (Human))
GI Therapeutics, Inc.

US Patent
LigandPNGBDBM253935(US9464092, AA | US9527857, AA)
Affinity DataIC50:  0.5nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Homo sapiens (Human))
GI Therapeutics, Inc.

US Patent
LigandPNGBDBM253926(US9464092, R | US9527857, R)
Affinity DataIC50:  0.5nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMelanin-concentrating hormone receptor 1(Homo sapiens (Human))
GlaxoSmithKline

Curated by ChEMBL
LigandPNGBDBM50241083(6-(4-chlorophenyl)-3-(3-methoxy-4-(2-(pyrrolidin-1...)
Affinity DataIC50:  0.5nMAssay Description:Antagonist activity against human MCHR1 expressed in CHO cells by luciferase reporter gene assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Homo sapiens (Human))
GI Therapeutics, Inc.

US Patent
LigandPNGBDBM253935(US9464092, AA | US9527857, AA)
Affinity DataIC50:  0.5nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Homo sapiens (Human))
GI Therapeutics, Inc.

US Patent
LigandPNGBDBM253926(US9464092, R | US9527857, R)
Affinity DataIC50:  0.5nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Homo sapiens (Human))
GI Therapeutics, Inc.

US Patent
LigandPNGBDBM253935(US9464092, AA | US9527857, AA)
Affinity DataIC50:  0.5nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Homo sapiens (Human))
GI Therapeutics, Inc.

US Patent
LigandPNGBDBM253926(US9464092, R | US9527857, R)
Affinity DataIC50:  0.5nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Homo sapiens (Human))
GI Therapeutics, Inc.

US Patent
LigandPNGBDBM253925(US10189849, Compound 28 | US10927120, Compound 28 ...)
Affinity DataIC50:  0.600nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Homo sapiens (Human))
GI Therapeutics, Inc.

US Patent
LigandPNGBDBM253925(US10189849, Compound 28 | US10927120, Compound 28 ...)
Affinity DataIC50:  0.600nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Homo sapiens (Human))
GI Therapeutics, Inc.

US Patent
LigandPNGBDBM253925(US10189849, Compound 28 | US10927120, Compound 28 ...)
Affinity DataIC50:  0.600nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Homo sapiens (Human))
GI Therapeutics, Inc.

US Patent
LigandPNGBDBM253925(US10189849, Compound 28 | US10927120, Compound 28 ...)
Affinity DataIC50:  0.627nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Homo sapiens (Human))
GI Therapeutics, Inc.

US Patent
LigandPNGBDBM253925(US10189849, Compound 28 | US10927120, Compound 28 ...)
Affinity DataIC50:  0.627nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCathepsin K(Homo sapiens (Human))
GlaxoSmithKline

Curated by ChEMBL
LigandPNGBDBM50138879(CHEMBL345982 | [(S)-1-(5-Phenyl-1H-pyrazol-3-ylami...)
Affinity DataIC50:  0.650nMAssay Description:Concentration required to inhibit 50% of cysteine protease cathepsin K of humanMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Homo sapiens (Human))
GI Therapeutics, Inc.

US Patent
LigandPNGBDBM253929(US9464092, U | US9527857, U)
Affinity DataIC50:  0.655nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Homo sapiens (Human))
GI Therapeutics, Inc.

US Patent
LigandPNGBDBM253929(US9464092, U | US9527857, U)
Affinity DataIC50:  0.655nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Homo sapiens (Human))
GI Therapeutics, Inc.

US Patent
LigandPNGBDBM253918(US9464092, J | US9527857, J)
Affinity DataIC50:  0.700nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Homo sapiens (Human))
GI Therapeutics, Inc.

US Patent
LigandPNGBDBM253918(US9464092, J | US9527857, J)
Affinity DataIC50:  0.700nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Homo sapiens (Human))
GI Therapeutics, Inc.

US Patent
LigandPNGBDBM253957(US10189849, Compound 39 | US10927120, Compound 39 ...)
Affinity DataIC50:  0.700nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Homo sapiens (Human))
GI Therapeutics, Inc.

US Patent
LigandPNGBDBM253918(US9464092, J | US9527857, J)
Affinity DataIC50:  0.700nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Homo sapiens (Human))
GI Therapeutics, Inc.

US Patent
LigandPNGBDBM253957(US10189849, Compound 39 | US10927120, Compound 39 ...)
Affinity DataIC50:  0.700nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Homo sapiens (Human))
GI Therapeutics, Inc.

US Patent
LigandPNGBDBM253929(US9464092, U | US9527857, U)
Affinity DataIC50:  0.700nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Homo sapiens (Human))
GI Therapeutics, Inc.

US Patent
LigandPNGBDBM253929(US9464092, U | US9527857, U)
Affinity DataIC50:  0.700nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Homo sapiens (Human))
GI Therapeutics, Inc.

US Patent
LigandPNGBDBM253957(US10189849, Compound 39 | US10927120, Compound 39 ...)
Affinity DataIC50:  0.700nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 1601 total ) | Next | Last >>
Jump to: